We have isolated stably transfected mouse embryonic fibroblast cell lines that inducibly express either the mature encephalomyocarditis virus (EMCV) or hepatitis A virus (HAV) 3C protease and have used these cells to demonstrate that both proteins are subject to degradation in vivo by the ubiquitin/26S proteasome system. The detection of 3C protease expression in these cells requires inducing conditions and the presence of one of several proteasome inhibitors. Both 3C proteases are incorporated into conjugates with ubiquitin in vivo. HAV 3C protease expression has deleterious effects on cell viability, as determined by observation and counting of cells cultured in the absence or presence of inducing conditions. The EMCV 3C protease was found to be preferentially localized to the nucleus of induced cells, while the HAV 3C protease remains in the cytoplasm. The absence of polyubiquitinated EMCV 3C protease conjugates in nuclear fraction preparations suggests that localization to the nucleus can protect this protein from ubiquitination.
Introduction
Successful replication of Picornaviridae family members depends to a large extent upon the ability of these viruses to commandeer host cell protein synthesis machinery, generate viral proteins at the required concentrations in a coordinated manner, and limit the ability of cellular processes to interfere with viral RNA replication, protein production, and virion assembly (for reviews see Bedard and Semler, 2004; Lloyd, 2005; Weidman et al., 2003) . The entire genome of these positive-sense RNA viruses is translated via a cap structureindependent, IRES-directed mechanism as a single, approximately 250 kDa concatenated polyprotein that is processed primarily by viral genome-encoded proteases. In addition to their essential involvement in the maturation of functional viral proteins, including themselves, from polyprotein precursors, it is becoming apparent that picornaviral proteases are key players in establishing an intracellular environment that can support virus replication. Several examples of picornaviral 2A and 3C protease-mediated cleavage of nuclear and cytoplasmic proteins required for host cellular transcription and mRNA translation have been reported (Amineva et al., 2004; Belsham et al., 2000; Devaney et al., 1988; Etchison et al., 1982; Falk et al., 1990; Haghighat et al., 1996; Hambidge and Sarnow, 1992; Joachims et al., 1999; Kerekatte et al., 1999; Krausslich et al., 1987; Kuyumcu-Martinez et al., 2004; Sommergruber et al., 1994; Tesar and Marquardt, 1990; Weidman et al., 2003; Ziegler et al., 1995a Ziegler et al., ,1995b , and 3C protease activity has been shown to disrupt NF-κB-dependent innate immune responses and induce caspase-dependent apoptosis as part of the infectious cycle of many picornaviruses (Barco et al., 2000; Deszcz et al., 2005; Neznanov et al., 2005) .
Important factors which must impact the effectiveness of picornaviral protease function are the absolute and relative concentrations of these enzymes during various stages of the Virology 360 (2007) 350 -363 www.elsevier.com/locate/yviro replication cycle. Equimolar synthesis of picornaviral proteins as part of the initial polyprotein requires that differences in cellular concentrations of mature viral proteins be determined by differences in maturation rates and in the rates of their subsequent degradation. For example, we have shown that the rapid degradation rate of mature EMCV 3C protease in virusinfected cells can be a factor in determining its concentration relative to other viral proteins (Lawson et al., 1989) . The inability to detect mature 3C protease in hepatitis A virus (HAV)-infected cells (Jia et al., 1991) may also be explained by a rapid in vivo turnover rate. We have found that both the EMCV and HAV 3C proteases and certain of their 3C proteasecontaining polyprotein precursors are substrates in vitro for rapid, selective degradation by the ubiquitin/26S proteasome system (Gladding et al., 1997; Lawson et al., 1994 Lawson et al., , 1999 Losick et al., 2003) . This system selectively tags substrate proteins at primary amines with polymeric ubiquitin chains through an enzymatic cascade requiring the ubiquitin-activating enzyme (E1) and specific ubiquitin-conjugating protein and ubiquitin-protein ligase (E2/E3) pairs. The resulting polyubiquitin-protein conjugates are recognized and degraded by the 26S proteasome complex (for reviews see Ciechanover et al., 2000; DeMartino and Slaughter, 1999; Glickman and Ciechanover, 2002; Hendil and Hartmann-Petersen, 2004; Passmore and Barford, 2004; Pickart, 2001) . While in vitro experiments have revealed details about interactions between the EMCV and HAV 3C proteases and the ubiquitin-conjugating pathway proteins that recognize them (Lawson et al., 1999 (Lawson et al., , 2001 , direct evidence that the ubiquitin/26S proteasome system is responsible for degrading these proteins in vivo has been lacking. It is possible that association with other proteins, compartmentalization, or other events sequesters the 3C proteases from the cellular ubiquitinating machinery in vivo.
We report here the results of experiments designed to determine whether the EMCV and HAV 3C proteases are degraded in vivo by the ubiquitin/26S proteasome system and whether the accumulation of these proteins in cells produces obvious cytotoxic effects. We prepared mouse embryonic fibroblast cell lines stably transfected with cloned genes coding for either the EMCV or HAV 3C protease under the control of the inducible synthetic heterodimeric ecdysone/retinoid-Xreceptor protein. We found that the presence of a proteasome inhibitor was required for expressing detectable levels of both proteins under inducing conditions and for maintaining the proteins at detectable levels for extended periods of time. High molecular mass proteins precipitated from induced whole cell lysates using anti-3C protease antibodies were shown to crossreact with anti-ubiquitin antibodies. These results demonstrate that the 3C proteases are ubiquitinated and degraded by the ubiquitin/26S proteasome system in vivo. The requirement for a proteasome inhibitor to accumulate the expressed 3C proteins complicated our attempts to monitor 3C protease-dependent cytotoxicity, because these inhibitors produce predictable and unrelated cytotoxic effects on their own. We did, however, observe greater cytotoxic effects on induced cells expressing the HAV 3C protease than on uninduced or control cell lines. An examination of nuclear and cytoplasmic fractions of induced cells revealed the localization of significant quantities of mature EMCV 3C protease to the nucleus, where it appears to be sequestered from ubiquitination. In contrast, the HAV 3C protease remained localized in the cytoplasm.
Results
The EMCV and HAV 3C proteases are degraded in vivo by the ubiquitin/26S proteasome system Stably transfected, inducible mouse cell lines that express the EMCV or HAV 3C proteases were prepared for the experiments described in this study using the two-plasmid Complete Control inducible mammalian expression system (Stratagene), which includes the pERV3 and pEGSH plasmids. For cells transfected with both plasmids, transcription is induced upon recruitment of a transcriptional co-activator to the receptor protein/promoter complex following binding of ecdysone (or the hormone analog ponasterone A) by the receptor protein (Chen et al., 1996; No et al., 1996) . NIH3T3 cells stably transfected with pERV3 and confirmed to constitutively express the ecdysone/retinoid-Xreceptor (ER-NIH3T3 cells) were subsequently transfected with pEGSH constructs carrying sequences encoding either the EMCV 3C protease with an N-terminal methionine or the HAV 3C protease with an N-terminal methionine-glycine. Over 100 colonies were selected from each transfection for their ability to survive simultaneous G418 and hygromycin challenge. Of these, 40-50 colonies from each transfection were screened by Western blot analysis of whole cell lysates for the expression of the 3C proteins under inducing conditions.
As expected, 3C protease could be not be detected in any of the isolated transfected cell lines in the absence of ponasterone A treatment. In addition, none of the hygromycin-resistant cell lines produced detectable 3C protease levels under inducing conditions in the absence of one of several specific, membranepermeable inhibitors of the 26S proteasome. Five different proteasome inhibitors were tested, including the reversible z-Leu-Leu-Leu-CHO (MG132), z-Leu-Leu-Phe-CHO (z-LLL-CHO), z-Leu-Leu-Nva-CHO (MG115), and z-Leu-Leu-Leu-B (OH) 2 (MG262), and the irreversible inhibitor clasto-lactacystin β-lactone (lactacystin). Each of these compounds has inhibitory activity toward 26S proteasome-dependent protein degradation in vivo with varying IC 50 values (Craiu et al., 1997; Dick et al., 1997; Fenteany and Schreiber, 1998; Goldberg, 1996, 1998; Lopes et al., 1997; McCormack et al., 1997; Orlowski et al., 1997; Palombella et al., 1994; Rock et al., 1994; Schauer et al., 1998) . Lactacystin, an inhibitor of the β-catalytic subunit of the proteasome, has been recognized to be particularly specific for inhibiting proteasome-dependent catalysis (Craiu et al., 1997; Dick et al., 1997; Fenteany and Schreiber, 1998) . All of these inhibitors were found to allow both the EMCV and HAV 3C proteases to accumulate to detectable levels in cells under inducing conditions. This provides a strong indication that both proteins are highly susceptible to in vivo degradation by the proteasome. Approximately 10% of the isolated colonies screened demonstrated significant levels of either 3C protease expression in the presence of inducing conditions and a proteasome inhibitor. All of these cell lines displayed similar induction time courses under these conditions, with the induced proteins becoming detectable by immunoblotting of whole cell lysate preparations between 8 and 12 h post-induction and maximum levels of the 3C proteases accumulating between 12 and 20 h post-induction (Figs. 1A and B) . Levels of 3C protease accumulating in induced cells were found to depend upon the concentration of inhibitor included (Figs. 1C and D) . The range of inhibitor concentrations selected for these experiments was based upon their published K i or in vivo IC 50 values, although it should be noted that these values are likely to vary with cell type. The results shown in Fig. 2 demonstrate the requirement for both inducing conditions and a proteasome inhibitor to allow expressed 3C protease detection.
To confirm directly that the accumulation of the 3C proteases in the induced cells is the result of proteasome inhibition, cells were incubated with the reversible inhibitor MG132 along with ponasterone A to generate pools of stably expressed 3C proteases, and the cells were incubated for additional time in inducing media either containing or lacking MG132. As shown in Fig. 3 , the removal of the inhibitor resulted in a more rapid reduction in the levels of both the EMCV and HAV 3C proteases relative to the levels accumulating in cells still exposed to the inhibitor. By 4 h after inhibitor removal, the accumulated Demonstration that both ponasterone A and proteasome inhibition are required for expressed 3C protease detection. pEGSH-E3C-or pEGSH-H3C-transfected cells were placed in medium containing no additives, ponasterone A only, 25 μM MG132 only, or both ponasterone A and 25 μM MG132 and incubated for 16 h at 37°C in 5% CO 2 . The cells were harvested and lysed and 50 μg of lysate protein from each sample was analyzed by SDS-PAGE and Western blotting using either anti-EMCV 3C protease or anti-HAV 3C protease antibodies. Lanes containing purified EMCV or HAV 3C protease marker proteins are indicated by 'M'. Fig. 3 . Comparison of expressed EMCV and HAV 3C protease levels after proteasome inhibitor removal. pEGSH-E3C-or pEGSH-H3C-transfected cells were placed in medium containing ponasterone A and 25 μM MG132 and incubated for 16 h at 37°C in 5% CO 2 . The inducing medium was replaced with fresh inducing medium or inducing medium containing MG132, and the cells were incubated at 37°C in 5% CO 2 . The cells were harvested and lysed at the indicated times following media change and 50 μg of lysate protein from each sample was analyzed by SDS-PAGE and Western blotting using either anti-EMCV 3C protease or anti-HAV 3C protease antibodies. concentrations of both 3C proteases were reduced by 50% or more. This is about the time previously shown to allow for complete reversibility of MG132-dependent proteasome inhibition in cultured cells (Lee and Goldberg, 1996) .
Inhibition of proteasome-mediated in vivo degradation of the EMCV and HAV 3C proteases would be expected to be accompanied by the synthesis and accumulation of polyubiquitin-3C protease conjugates if the ubiquitin/26S proteasome system is indeed responsible for the observed in vivo 3C protease proteolysis. Candidate high molecular mass polyubiquitin conjugates were difficult to identify in the anti-3C protease antibody-developed Western blots used to analyze the induced whole cell lysates, possibly due to incomplete inhibition of proteasome activity combined with the presence of cellular proteins cross-reacting with our antibodies. We therefore performed double antibody recognition experiments to detect conjugates synthesized in cells under inducing conditions in the presence of MG132. We selected this inhibitor because it routinely supported the highest level of 3C protease protein accumulation (Fig. 1) . Large-scale 16-h inductions of 3C protease expression were carried out and the whole cell lysates were subjected to mock immunoprecipitation without antibody or immunoprecipitation with either anti-EMCV 3C protease or anti-HAV 3C protease antibodies, and the precipitates were subjected to SDS-PAGE and Western blotting. The blots were developed using primary anti-3C protease or anti-ubiquitin antibodies. Immunoprecipitates from induced cell lysates analyzed by anti-3C protease antibody-developed Western blots were found to contain immunoprecipitated EMCV or HAV 3C protease proteins (Figs. 4A and B, respectively) , as well as certain higher molecular mass proteins which might represent polyubiquitin-3C protease conjugates. These proteins are absent in the mock immunoprecipitated sample lanes and in the lanes containing immunoprecipitated lysate samples from uninduced cells. Blots developed using anti-ubiquitin antibodies revealed the presence of a heterogeneous mixture of ubiquitin-containing proteins migrating with apparent masses greater than the 3C proteases and including a distinct ladder pattern, but only in sample lanes containing induced cell lysates from the EMCV 3C proteaseexpressing ( Fig. 4A ) or HAV 3C protease-expressing ( Fig. 4B ) cell lines that were immunoprecipitated with the respective anti-3C protease antibody. The migration pattern of the proteins in these lanes is characteristic of polyubiquitinated conjugates detected with anti-ubiquitin antibodies. These results confirm that both the EMCV and HAV 3C proteases are polyubiquitinated in vivo, undoubtedly as a prerequisite to 26S proteasome recognition.
While we used a mouse cell line expression system to evaluate the susceptibility of the EMCV and HAV 3C proteases to in vivo ubiquitination, human and some primate cells are the natural host for HAV (Bayalan, 1992) . To confirm that human cells possess HAV 3C protease-ubiquitinating activity, we tested the ability of HeLa cell extracts to catalyze HAV 3C protease ubiquitination. Methylated ubiquitin was used in these assays because it cannot support the synthesis of polymeric ubiquitin conjugates and facilitates the detection of ubiquitin- Fig. 4 . Detection of ubiquitin-3C protease conjugates in cells cultured under inducing conditions. pEGSH-E3C-or pEGSH-H3C-transfected cells were placed in medium containing either 25 μM MG132 (non-inducing conditions, 'Unind') or ponasterone A and 25 μM MG132 (inducing conditions, 'Ind') and incubated for 16 h at 37°C in 5% CO 2 . The cells were harvested and lysed and 225 μg aliquots of lysate protein were immunoprecipitated in the absence (−) or presence (+) of the appropriate anti-3C protease antibodies (Ab). The immunoprecipitated samples were then subjected to SDS-PAGE and Western blotting using either anti-3C protease antibodies or anti-ubiquitin antibodies. One of the functions of the ubiquitin/26S proteasome system is to eliminate misfolded proteins (Glickman and Ciechanover, 2002) . To confirm that the 3C proteases expressed in our cell lines are catalytically active, and therefore correctly folded, we tested whole cell lysates prepared from cells cultured under inducing conditions in the presence of a proteasome inhibitor for their ability to catalyze the cleavage of in vitro synthesized viral polyprotein substrates. As shown in Fig. 6A lysates prepared from induced EMCV 3C protease-expressing cells contain an activity that catalyzes the cleavage of the leader (L) protein from the EMCV LVP0 polyprotein. The 2A protein was found to be cleaved from the HAV VP2-VP3-VP1-2A polyprotein by lysates prepared from induced HAV 3C protease-expressing cells. EDTA was included in these reaction mixtures to inhibit the ATP-dependent degradation of the 3C protease proteins. We have observed that purified EMCV 3C protease much more efficiently catalyzes viral polyprotein substrate cleavage than does purified HAV 3C protease. This kinetic difference likely accounts for the longer incubation time required to detect the in vivo expressed HAV 3C protease cleavage products and the relatively small quantity of products observed.
Effects of 3C protease expression on cell viability
We have hypothesized that the rapid destruction of the EMCV and HAV 3C proteins might be necessary to prevent 3C protease-mediated damage that is detrimental to virus replication, and we hoped to test this idea with our stably transfected cell lines. Our attempts to evaluate the cytotoxic effects of the 3C proteases post-induction were complicated, however, by the need to prevent their simultaneous proteasome-dependent degradation. All of the proteasome inhibitors used in this study resulted in visible cytotoxic effects, in the form of general morphological changes, a reduction in growth rate, and eventually cell death. The extent of these effects was dependent upon the particular inhibitor and inhibitor concentration used, but for all of the inhibitors the effects typically became noticeable after about 12 to 16 h of incubation and increased as a function of time thereafter. These effects are to be expected, because it is known that long-term exposure of cells to agents that compromise proteasome function has detrimental effects on a number of cellular processes and can trigger apoptotic pathways (Wójcik, 2002) . We carried out extensive testing of several proteasome inhibitors over a wide range of concentrations to evaluate the extent to which they cause obvious cytotoxic effects during a 24-h exposure period while still enabling the accumulation of a detectable level of the 3C proteins under inducing conditions. We observed during the course of these tests that relatively low concentrations of the highly specific proteasome inhibitor lactacystin minimized inhibitor-induced cytotoxicity. The induction of 3C protease expression was therefore performed in the presence of 10 μM lactacystin in order to assay 3C protease-dependent cytotoxicity above that caused by the presence of a proteasome inhibitor.
We performed a systematic evaluation of the effect of the EMCV and HAV 3C proteases on cell viability under both inducing and non-inducing conditions in the presence or absence of lactacystin. To control for non-protease specific effects, we performed the same analysis on untransfected ER-NIH3T3 cells as well as ER-NIH3T3 cells stably transfected with pEGSH-Luc, a control plasmid that allows for inducible expression of firefly luciferase protein, which is detectable with Fig. 6 . Evaluation of expressed EMCV and HAV 3C protease catalytic activity. pEGSH-E3C-or pEGSH-H3C-transfected cells were placed in medium containing either 50 μM MG132 (non-inducing conditions, 'Unind') or ponasterone A and 50 μM MG132 (inducing conditions, 'Ind') and incubated for 16 h at 37°C in 5% CO 2 . The cells were harvested and lysed in a hypotonic buffer. 3C protease catalytic activity reaction mixtures containing either these lysate preparations or purified 3C protease (control reactions) and 35 S-labeled viral polyprotein substrates were incubated at 30°C and aliquots were removed at the indicated times for analysis by SDS-PAGE and phosphorimaging. (A) Analysis of the cleavage of the EMCV LVP0 polyprotein by pEGSH-E3C-transfected cell lysates or purified EMCV 3C protease. (B) Analysis of the cleavage of the HAV VP2-VP3-VP1-2A polyprotein by pEGSH-H3C-transfected cell lysates or purified HAV 3C protease. The gel was deliberately overexposed to facilitate visualization of the cleavage products. The location of the HAV 2A cleavage product from the reaction mixture containing lysate from HAV 3C protease-expressing cells cultured under inducing conditions is indicated by '*'.
anti-luciferase antibodies under our inducing conditions in the absence of a proteasome inhibitor (data not shown).
Our observations over a 24-h incubation period revealed that the ER-NIH3T3 cells are detrimentally affected by lactacystin, regardless of whether they express the 3C proteases, luciferase, or neither. These effects became noticeable by approximately 12 h, but they were most severe in cells expressing the HAV 3C protease (transfected with pEGSH-H3C). By 16 h it was clear that for cells incubated in media containing lactacystin the presence of the HAV 3C protease affected cell viability when compared to the same cells under non-inducing conditions (Fig.  7A ). These differences were not observed in cells expressing the EMCV 3C protease (transfected with pEGSH-E3C) or with either control cell line. No differences were observed with any of the cell lines cultured under non-inducing vs. inducing conditions in the absence of the proteasome inhibitor (Fig. 7A) . These results were reproducible across our isolated, stably transfected cell lines. Our interpretation of these observations was confirmed by the quantification of the number of viable cells remaining in each culture after 20 h. As shown in Fig. 7B , in the absence of lactacystin there were no significant differences in the percentage of living control, EMCV 3C protease-expressing, or HAV 3C protease-expressing cells remaining in the cultures subjected to inducing conditions relative to cells incubated in the non-inducing medium. In the presence of the proteasome inhibitor, however, a significantly smaller fraction of the HAV 3C protease-expressing cells subjected to inducing conditions retained viability (Fig. 7C) . These results indicate that the expression of the HAV 3C protease, under conditions of at least partial proteasome inhibition, negatively impacts cell viability. Our data indicate that EMCV 3C protease expression under similar conditions does not contribute to cytotoxicity, but effects on cell growth mediated by this protein could easily be masked by those resulting from incubation with the proteasome inhibitor. It does not appear that the inducing conditions alone can account for any additional level of cytotoxicity beyond that due to the inhibitor, because neither the untransfected cells nor the luciferase-expressing cells were affected by incubation with ponasterone A in the presence or absence of lactacystin.
Subcellular localization of the expressed 3C proteases
The poliovirus, human rhinovirus, and EMCV 3C proteases have been shown to be trafficked to the nuclear compartment in infected cells (Aminev et al., 2003 (Aminev et al., , 2004 Sharma et al., 2004; Weidman et al., 2003) . The 3D RNA polymerase proteins of several picornaviruses contain a nuclear localization signal (NLS) (Dingwall and Laskey, 1991 ), which appears to be responsible for the translocation of the 3D protein and 3D-containing precursors across the nuclear membrane (Aminev et al., 2003; Diamond and Kirkegaard, 1994; Sharma et al., 2004) . Subsequent processing within the nucleus apparently releases free 3C protease. The cleavage of transcription factors in the nucleus is emerging as an important function of at least some picornavirus 3C proteases, making the issue of nuclear trafficking important. We therefore examined whether the mature EMCV and HAV 3C proteases localize to the nucleus in the absence of other viral proteins.
Soluble cytoplasmic and nuclear extracts were prepared from cell lines expressing the EMCV and HAV 3C proteases in the presence of MG132. Analysis by SDS-PAGE and Western blotting of the cytoplasmic and nuclear fractions prepared from cells incubated under inducing conditions for 16 h revealed the presence of the EMCV 3C protease in both fractions, with the majority associated with the nuclear fraction (Fig. 8A) . The HAV 3C protease, on the other hand, was found only in the cytoplasmic fraction (Fig. 8B) . The partitioning of the nuclear and cytoplasmic proteins in these experiments was confirmed using glyceraldehyde 3-phosphate dehydrogenase (G3PDH) and poly-ADP-ribose-polymerase (PARP) as cytoplasmic and nuclear marker proteins, respectively (Dastoor and Dreyer, 2001; Hara et al., 2005; Minaschek et al., 1992) . The unequal distribution of these proteins between the subcellular fractions indicates that the general structural integrity of the nuclear membrane has not been compromised by the inducing conditions or presence of the proteasome inhibitor. While G3PDH lacks an NLS and is typically localized primarily in the cytoplasm, it has recently been found that a significant fraction of this protein is translocated into the nuclear compartment under conditions of stress-induced apoptosis (Dastoor and Dreyer, 2001; Hara et al., 2005; Kim et al., 2006) . We found that neither our inducing conditions nor proteasome exposure altered the partitioning of G3PDH in our experiments (data not shown).
Our results show that a substantial fraction of the mature EMCV 3C protease is preferentially localized to the nucleus, while the HAV 3C protease is not, at least under conditions of reduced proteasome activity. Because the nuclear compartment is known to contain ubiquitin-conjugating pathway enzymes and the proteasome complex (for review see von Mikecz, 2006) , an interesting question is whether 3C proteins localized to the nucleus are degraded by the nuclear ubiquitin/26S proteasome system. To answer this question we performed double antibody recognition experiments with nuclear fractions prepared from EMCV 3C protease-expressing cells cultured under noninducing or inducing conditions for 16 h in the presence of MG132. Samples were subjected to immunoprecipitation with anti-EMCV 3C protease antibodies, followed by SDS-PAGE and Western blotting with either anti-3C protease or antiubiquitin antibodies. As shown in Fig. 9 , anti-3C protease antibody-precipitated proteins included little or none of the high molecular mass polyubiquitinated EMCV 3C protease conjugates detected in induced whole cell lysates. (Compare the induced cell nuclear fraction protein sample immunoprecipitated with anti-3C protease antibodies and blotted with antiubiquitin antibodies in Fig. 9 with the similarly immunoprecipitated and blotted induced whole cell lysate sample in Fig. 4A ). Consistent with this result, we found that the nuclear extract preparations do not support the ubiquitination of purified 3C proteases in the presence of methylated ubiquitin and an ATPregenerating system (data not shown). These results suggest that Fig. 8 . Cytoplasmic vs. nuclear distribution of the expressed EMCV 3C and HAV 3C proteases. pEGSH-E3C-or pEGSH-H3C-transfected cells were placed in medium containing ponasterone A and 25 μM MG132 and incubated for 16 h at 37°C in 5% CO 2 . The cells were harvested and cytoplasmic (C) and nuclear (N) extracts prepared as described in Materials and methods. Samples from EMCV 3C protease-expressing cells (panel A) and HAV 3C protease-expressing cells (panel B) containing 20 μg of protein were analyzed by SDS-PAGE and Western blotting with antibodies against EMCV 3C protease, HAV 3C protease, glyceraldehyde 3-phosphate dehydrogenase (G3PDH; cytoplasmic marker protein), or poly-ADP-ribose-polymerase (PARP; nuclear marker protein).
the EMCV 3C protease localized to the nucleus is not incorporated in vivo into conjugates with ubiquitin.
Discussion
The mature EMCV 3C protease has been shown to be rapidly turned over in virus-infected cells and evidence consistent with the rapid proteolysis of the HAV 3C protease in infected cells has been reported (Jia et al., 1991; Lawson et al., 1989) . We have demonstrated that both of these 3C proteases, as well as certain 3C protease-containing polyprotein precursors, are substrates for rapid degradation by the ubiquitin/26S proteasome system in vitro (Lawson et al., 1994 (Lawson et al., , 1999 Losick et al., 2003) . Studies using purified, reconstituted ubiquitin-conjugating reaction systems have revealed that both the EMCV and HAV 3C proteases are recognized by three different ubiquitinconjugating pathways (Lawson et al., 1999 (Lawson et al., , 2001 Schlax and Lawson, unpublished) , suggesting a strong evolutionary pressure for the degradation of these proteins. Evidence directly demonstrating the ubiquitin-mediated in vivo destruction of the EMCV and HAV 3C proteases has been lacking, however. This is an important point, because it is possible that one or more other proteases, and not the 26S proteasome, are responsible for 3C protease degradation in intact cells.
To answer the question of whether the ubiquitin/26S proteasome system is responsible for EMCV and HAV 3C protease degradation in cells and to attempt to answer questions regarding 3C protease cytotoxicity we prepared mouse NIH3T3 cell lines stably transfected with genes coding for the mature 3C proteases under the control of a promoter activated by a synthetic heterodimeric ecdysone/retinoid-X-receptor protein.
We found that our ability to detect the expression of both 3C proteases in the cells required the presence of both the inducing agent and one of several different cell-permeable inhibitors of proteasome proteolytic activity, demonstrating that the 26S proteasome at least contributes to the in vivo degradation of both proteins. Of the inhibitor compounds tested the reversible inhibitor MG132 proved to consistently allow the highest level of 3C protease expression in our cells. Another inhibitor, lactacystin, required media concentrations ten times the reported IC 50 value of 1 μM for detectable levels of both 3C proteases to accumulate under inducing conditions, even though this compound is known to be the most specifically directed of our inhibitor set against proteasome proteolytic activity (Craiu et al., 1997; Dick et al., 1997; Fenteany and Schreiber, 1998) . Even in the presence of 20 μM lactacystin the expressed protein levels remained well below those achieved in the presence of MG132, which was typically provided at a concentration five times the published IC 50 value of 5 μM. The limited effectiveness of lactacystin in supporting 3C protease accumulation under the inducing conditions may be a function of the cell line we used for the stable transfections, but it could also mean that other cellular proteases contribute to the in vivo destruction of the 3C proteins. Even if this is the case, additional evidence confirming the significant, if not exclusive, involvement of the ubiquitin/26S proteasome system in the in vivo degradation of both the EMCV and HAV 3C proteases was obtained from experiments which showed that both of the expressed 3C proteases are incorporated in vivo into conjugates with polyubiquitin.
We have hypothesized that the degradation of the mature EMCV and HAV 3C proteases may be a necessary part of their respective viral replication cycle. It is conceivable, for example, that the accumulation of these 3C proteases in infected cells could interfere with efficient virus replication by cleaving one or more host proteins required for host cell viability. In conjunction with the experiments described here, we attempted to determine whether proteasome inhibitors result in 3C protease accumulation in virus-infected cells and whether this accumulation interferes with viral replication efficiency. We discovered, however, that infections could not be established in proteasome inhibitor-treated cells, rendering these studies impossible to perform. We therefore performed experiments designed to determine whether either the EMCV or HAV 3C protease, expressed in our stably transfected cell lines, is on its own toxic to cells. Our efforts were hampered by the onset of cytotoxic effects resulting from the necessary inclusion of a proteasome inhibitor in the media during induction of 3C protease gene expression. Proteasome inhibitors have been shown to induce apoptosis in dividing cells (Wójcik, 2002) , so the effects of the inhibitors on our cell lines are not surprising. In spite of this complication we obtained evidence from observations and cell counting that the induction of HAV 3C protease synthesis in the presence of a proteasome inhibitor resulted in a greater fraction of the cells dying within a 20-h period than in the presence of the inhibitor without induced 3C protease expression. This suggests that the HAV 3C protease has a detrimental impact on cell viability, at least under Fig. 9 . Evaluation of EMCV 3C protease-expressing cell nuclear fraction for the presence of ubiquitin-EMCV 3C protease conjugates. pEGSH-E3C-transfected cells were placed in medium containing either 25 μM MG132 (non-inducing conditions, 'Unind') or ponasterone A and 25 μM MG132 (inducing conditions, 'Ind') and incubated for 16 h at 37°C in 5% CO 2 . The cells were harvested and nuclear fractions prepared as described in Materials and methods. One hundred μg aliquots of nuclear fraction protein were immunoprecipitated in the absence (−) or presence (+) of anti-EMCV 3C protease antibodies. The immunoprecipitated samples were then subjected to SDS-PAGE and Western blotting using either anti-EMCV3C protease antibodies or anti-ubiquitin antibodies. The lane containing purified EMCV 3C protease marker proteins is indicated by 'M'.
conditions in which proteasome activity is at least partially reduced. We attempted to isolate cell lines expressing the mutated HAV 3C(C172A) protein to determine whether the HAV 3C protease-caused cytotoxicity requires the catalytically active protein. While we were able to isolate a large number of G418-and hygromycin-resistant colonies following transfection with pEGSH carrying the HAV 3C(C172A) gene, we could not detect HAV 3C(C172A) protein expression in any of the transfected cell lines. We have found in our laboratory that point mutations in the catalytic region of the HAV 3C protease can alter folding stability and solubility, so it is possible that an intact in vivo expressed HAV 3C(C172A) protein is not able to accumulate.
We observed that EMCV 3C protease expression resulted in no obvious cytotoxicity beyond that caused by the proteasome inhibitor. This does not prove that the EMCV 3C protein does not interfere with processes required for cell viability, because damaging effects caused by the 3C protease accumulation in induced cells may be masked by the effects of the lactacystin used in these experiments. It is important to note that in vivo expression of the EMCV 3C protease has been previously achieved in cells stably transfected with the cloned gene under the control of the mouse metallothionine (mMT-I) promoter (Lawson et al., 1989) , but in that case a polyprotein chimera containing the carboxyl terminal portion of the 3A protein, the entire 3B and 3C proteins, and the N-terminal region of the 3D RNA polymerase (3A'BCD' polyprotein) was the primary product. This earlier expression system also had the undesirable requirement for a preliminary, long-term global inhibition of translation and exposure to Zn 2+ followed by the global inhibition of transcription. As in this study, the levels of accumulated induced expression products were low, and it was difficult to detect the mature 3C protease that resulted from the processing of the 3A'BCD' polyprotein. The expression of this version of the EMCV 3C protein also did not result in obvious cytotoxic effects to the cells, but the expressed products disappeared rapidly after the initial induction.
Because the 3C proteases of several picornaviruses, including EMCV, have been shown to be translocated into the nucleus of infected cells (Aminev et al., 2003 (Aminev et al., , 2004 Sharma et al., 2004; Weidman et al., 2003) , we examined the cytoplasmic vs. nuclear distribution of the EMCV and HAV 3C proteases in our expressing cell lines. We found that the EMCV 3C and HAV 3C proteases were unequally and differentially partitioned between cytoplasmic and nuclear fractions prepared from induced cells. Specifically, we detected little or no expressed HAV 3C protease in the nuclear fraction, suggesting that this protein is not translocated into, nor is tightly associated with, the nucleus. However, for the EMCV 3C protease, the 3C protein was isolated in both the nuclear and, to a lesser extent, cytoplasmic protein fractions. Although the biochemical sub-cellular fractionation procedure we used is designed to recover soluble nuclear extracts from whole cells, it is formally possible that the EMCV 3C protease we detected in the nuclear fraction is actually tightly associated in vivo with the nuclear membrane rather than translocated into the nuclear compartment. This is unlikely, however, because such a tight association with the nuclear membrane would be expected to sequester a significant fraction of the expressed 3C protease from degradation by the ubiquitin/26S proteasome system. The absolute requirement for proteasome inhibition to detect any 3C protease protein in the cells under inducing conditions argues that this does not occur.
Additionally, an examination of the EMCV 3C protease pool found in the nuclear fraction revealed an absence of polyubiquitinated conjugates, suggesting that the portion of the EMCV 3C protein which is localized to the nucleus is rendered unavailable to the ubiquitin-conjugating pathways that recognize this protein as a substrate. Consistent with this result, previous investigations in our laboratory have shown that the pathways which target the EMCV and HAV 3C proteases for ubiquitination are located in the cytoplasm and include cytoplasmic ubiquitin-conjugating pathway enzymes (Lawson et al., 1994 (Lawson et al., , 1999 (Lawson et al., , 2001 Losick et al., 2003; Schlax and Lawson, unpublished results) . These results, along with the fact that proteasome inhibition is required for the EMCV 3C protease to accumulate in our expressing cell lines under inducing conditions, are consistent with a scenario in which the mature EMCV 3C protein can move in both directions between the cytoplasm and nucleus but is subject to proteolysis only by the cytoplasmic ubiquitin/26S proteasome system. Aminev et al. have shown that the EMCV 3C protease enters the nucleus of virus-infected cells as part of the viral 3BCD polyprotein precursor and that this requires a nuclear localization signal in the 3D RNA polymerase segment of the chimera (Aminev et al., 2003) . This is the likely route by which most of the mature EMCV 3C protease is relocated into the nucleus in virus-infected cells. The fusion of the 3D RNA polymerase to the 3C protease inhibits 3C protease-targeted ubiquitination and renders the polyprotein relatively stable in vitro (Lawson et al., 1994) , so the majority of the 3C protein is likely to be found in 3D RNA polymerase-containing precursors. While our data reveal that a mechanism for the translocation of mature EMCV 3C protease into the nucleus may exist, such a mechanism may not function if the proteasome population is fully active. In addition, picornavirus infection can result in changes in the nuclear transport machinery, which, as was shown with polio-and rhinovirus, is accompanied by alterations in the nuclear pore complex Sarnow, 2001, 2002) . The nuclear translocation of picornaviral proteins in the absence of infection may therefore not accurately mimic events that occur during infection.
The results reported here provide the first direct evidence for the in vivo degradation of picornavirus proteins by the ubiquitin/26S proteasome system and forge an important link with studies characterizing in vitro ubiquitination and degradation of the EMCV and HAV 3C proteases. Given the crucial function served by picornavirus processing proteases in generating mature viral proteins and altering fundamental cellular processes to provide an environment necessary for virus replication, understanding the factors that influence 3C protease activity is imperative. Clearly, the degradation of the mature EMCV and HAV 3C proteases must serve to reduce the concentration of these proteins during infection, probably in a compartment-specific manner. Our finding that the mature EMCV 3C protease is sequestered from ubiquitination by nuclear localization suggests that mature EMCV 3C protease generated in the nucleus by the processing of viral polyprotein precursors in infected cells is probably also protected from rapid degradation. This would allow the protein to accumulate in the nucleus and raises the question of whether the EMCV 3C protease catalyzes the cleavage of certain nuclear proteins, as has been reported for the 3C proteases of some other picornaviruses (Amineva et al., 2004; Falk et al., 1990; Weidman et al., 2003) . The discovery that HAV 3C protease expression can reduce cell viability represents the first step in developing an explanation for why some 3C proteases have evolved into substrates for ubiquitin-mediated proteolysis.
Materials and methods

Chemicals, reagents, and cells
Protease inhibitor cocktail, hygromycin B, Dulbecco's modified Eagle's medium with 4500 mg/L glucose (DMEM), newborn calf serum, L-glutamine, penicillin-streptomycin, goat anti-rabbit and anti-mouse IgG alkaline phosphatase conjugates, and Staphylococus aureaus protein A Sepharose were from Sigma (St. Louis, MO). Mouse glyceraldehyde-3-phosphate dehydrogenase (G3PDH) monoclonal antibody was obtained from Chemicon International (Temecula, CA). Bovine poly-ADP-ribose-polymerase (PARP) monoclonal antibody was from eBioscience (San Diego, CA). Geneticin (G418 sulfate) was from Gibco Invitrogen Corporation (Carlsbad, CA). BCIP/ NBT and Lumi-Phos WB phosphatase substrates were from Kirkegaard and Perry Laboratories (Gaithersburg, MD) and Lumigen, Inc. (Southfield, MI), respectively. ECL Plus and ECF detection systems and L-[
35 S]-methionine were from Amersham Biosciences (Piscataway, NJ). Pfu DNA polymerase, ponasterone A, anti-luciferase antibodies, ER-NIH3T3 cell line, pEGSH, and pEGSH-Luc plasmids, and the accompanying license for the Complete Control inducible mammalian expression system were from Stratagene (La Jolla, CA). All restriction endonucleases were from New England Biolabs (Beverly, MA). NE-PER nuclear and cytoplasmic extraction reagents were from Pierce Biotechnology (Rockford, IL). Ubiquitin aldehyde, clasto-lactacystin β-lactone (lactacystin), z-Leu-Leu-Phe-CHO (z-LLF-CHO), z-Leu-Leu-Leu-CHO (MG132), z-Leu-Leu-Nva-CHO (MG115), z-Leu-Leu-Leu-B (OH) 2 (MG262), and HeLa cell S100 preparation were from Boston Biochem (Cambridge, MA). X-OMAT X-ray film was from Eastman Kodak Corporation (Rochester, NY). Immobilon-P 0.45 μM pore size polyvinylidene difluoride (PVDF) membrane was from Millipore Corporation (Billerica, MA). T7 in vitro transcription and rabbit reticulocyte in vitro translation systems were from Promega (Madison, WI). Polyclonal anti-EMCV 3C protease and anti-HAV 3C protease antibodies were raised in rabbits, using the 3C proteins purified as previously described from expressing E. coli cells as antigens, and were purified from sera by 3C protease affinity chromatography (Lawson et al., 1994) . Methylated ubiquitin was prepared as previously described (Hershko and Heller, 1985) . Antiubiquitin antibodies were the generous gift of Cecile Pickart. pE5LVP0 was kindly provided by Ann Palmenberg, and pEXT7-HM/HAS-VP2-2A/(E/S) was kindly provided by Christian Probst and Verna Gaus-Müller.
Plasmid constructions
pEGSH-E3C, carrying the EMCV 3C protease gene was constructed by PCR amplification of the EMCV 3C proteaseencoding sequence from pE3C (Gladding et al., 1997) . Coding strand (5′-TTTTGAATTCATGGGACCAAACCCTGTGATGG-3′) and non-coding strand (5′-AAAAGGATCCTTACT-GTGGCTCAAAGGCATTC-3′) PCR primers containing EcoRI and BamHI restriction endonuclease sites, respectively, were used to amplify and directionally subclone the 3C gene into the multiple cloning site of the ponasterone A-inducible mammalian transcription cassette of the pEGSH plasmid. This plasmid was then used as a template for "Quick Change" complementary primer pair directed mutagenesis (Stratagene; La Jolla, CA) to insert a strong in-frame translation start codon (Kozak, 1987) , embedded in an NcoI site, immediately upstream of the EMCV 3C gene, using the coding and non-coding strand primers 5′-CAGCAGAAGAGCAATTGC-CATGGGACCAAACCCTGTGATG-3′ and 5′-CATCA-CAGGGTTTGGTCCCATGGCAATTGCTCTTCTGCTG-3′, respectively. To construct pEGSH-H3C, carrying the HAV 3C protease gene, coding strand (5′-AAAAGAATTCCCATGGAAT-CTCAGTCAACTTTGGAAATAGC-3′) and non-coding strand (5′-AAAAGGATCCATCTGACTTTCAATTTTCTTATCAA-TATTTTGGAAC-3′) PCR primers were used to amplify the HAV 3C protease-encoding sequence from pHAV3C (Gladding et al., 1997) , and this was subcloned into the pEGSH plasmid as described above. The final insert sequences were confirmed via dideoxy sequence analysis (MWG Biotech; High Point, NC).
Mammalian cell propagation, transfection and colony screening
Unless stated otherwise, cells were grown as monolayer culture in DMEM containing 10% bovine calf serum, 100 units/ ml penicillin, 100 μg/ml streptomycin, and 2 mM glutamine (standard medium) at 37°C in 5% CO 2 , with either 200 μg/ml G418 (for the ER-NIH3T3 cell line) or 200 μg/ml G418 and 100 μg/ml hygromycin B (for the ER-NIH3T3/pEGSH-E3C, ER-NIH3T3/pEGSH-H3C, and ER-NIH3T3/pEGSH-Luc cell lines). Stable double transfectants were prepared using an Electro Cell Manipulator 600 electroporation device (BTX Inc.; San Diego, CA). Briefly, 10 × 10 6 ER-NIH3T3 mouse embryonic fibroblast (MEF) cells were transfected with 50 μg of AsnIlinearized pEGSH-E3C, pEGSH-H3C, or pEGSH-Luc plasmid DNA in a total volume of 0.5 ml. The transfected cells were added to 20 ml standard DMEM and grown in 150 mm tissue culture-treated plates for 24 h before challenging with 200 μg/ml hygromycin and 250 μg/ml G418. Following 14 to 20 days of hygromycin/G418 selection, the resulting individual colonies were picked, trypsinized and disaggregated, and expanded in 96 well plates for subsequent propagation and selection.
Colonies were screened for satisfactory levels of ponasterone A-inducible 3C protease protein or luciferase expression by SDS-PAGE and Western blotting analysis of lysates (see below) prepared from cells incubated for 16 or 20 h in standard media containing 10 μM ponasterone A and 25 μM MG132. To simplify the process of identifying the 3C protease-expressing colonies, we developed a combinatorial screening method in which cell lysates from groups of five individually induced colonies were pooled and analyzed. Colonies associated with lysate pools demonstrating detectable 3C protease expression were subsequently screened individually. About 10% of all screened colonies had detectable levels of 3C protease expression, and those having the highest levels of expression were used in subsequent experiments.
Detection of 3C protease expression and evaluation of proteasome inhibitor effects
For routine detection of 3C protease expression and the evaluation of proteasome inhibitor effects on 3C protease accumulation, cells were cultured in 24-or 12-well plates to 70 to 80% confluency in standard medium containing 200 μg/ ml G418 and 100 μg/ml hygromycin B. This medium was then replaced with standard medium containing either 10 μM ponasterone A, added from a stock ethanol solution (inducing medium), or standard medium containing an equivalent volume of ethanol (non-inducing medium). For experiments requiring the inclusion of a proteasome inhibitor, the inhibitor was dissolved in dimethyl sulfoxide (DMSO) and included in the media at the indicated concentration(s). When appropriate, control media containing equivalent volumes of DMSO alone were used. The cells were then incubated at 37°C in 5% CO 2 . Inductions were terminated at the indicated times by removing the media, washing the cells with phosphate-buffered saline (PBS), and then incubating the cells on ice for 20 min with RIPA lysate buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 1% Triton x-100, 1% sodium deoxycholate, and 0.1% sodium dodecyl sulfate). Lysate viscosity was reduced via the mechanical shearing of chromosomal DNA by multiple passes through a 200 μl micropipetor tip. The RIPA lysates were then cleared via centrifugation for 5 min at ∼ 15,000×g (4°C), transferred to clean tubes, and assayed for protein concentration using the Bradford reagent. For experiments designed to examine the effects of proteasome inhibitor removal on 3C protease stability, cells were incubated for 16 h in inducing medium containing 25 μM MG132, after which the medium was removed, and the cells were washed with PBS and then provided with fresh inducing medium containing 10 μM ponasterone A or inducing medium containing 10 μM ponasterone A and 25 μM MG132. The cells were then incubated for the indicated additional times at 37°C in 5% CO 2 and were processed and lysed as described above. Lysate samples containing 50 μg of protein were subjected to SDS-PAGE and Western blotting analysis using the appropriate primary anti-3C protease antibodies and alkaline phosphataseconjugated secondary antibodies. Purified 3C proteases were included as standards in all SDS-PAGE and Western blot analyses. The blots were developed using either Lumi-phos WB and X-ray film exposure or ECF alkaline phosphatase reagent and scanning with a Fuji FLA-5000 imaging system (473 nm excitation laser and 575 nm emission filter). For the detection of luciferase expression by control pEGSH-Luctransfected cells, the above procedure was used, except that the inducing medium did not include a proteasome inhibitor and Western blotting was carried out using primary antiluciferase antibodies.
Ubiquitin-3C protease conjugate detection
For experiments designed to detect polyubiquitin-3C protease conjugates generated in the cells under inducing conditions, the pEGSH-E3C-or pEGSH-H3C-transfected cells were cultured in 100 mm dishes to 70 to 80% confluency in standard medium containing 200 μg/ml G418 and 100 μg/ml hygromycin B. This medium was then replaced with either inducing medium containing 10 μM ponasterone A and 25 μM MG132 or non-inducing medium containing 25 μM MG132 and incubated for 16 h at 37°C in 5% CO 2 . The cells were washed with PBS and harvested by scraping with a rubber policeman into 1 ml PBS/plate. The cells were pelleted by centrifugation for 2 min at 1300×g, re-suspended in 10 volumes of fresh PBS, and pelleted again. The cells were re-suspended in approximately 10 volumes of RIPA buffer and the total protein concentration was determined using the Bradford reagent. 225 μg aliquots of whole cell total protein were mock immunoprecipitated, without antibody, or immunoprecipitated with anti-3C protease antibody as previously described (Lawson et al., 1994) . The precipitates were subjected to SDS-PAGE and Western blotting using anti-3C protease or anti-ubiquitin primary antibodies and alkaline phosphatase-conjugated secondary antibodies. The blots were developed using the ECF alkaline phosphatase reagent as described above.
In vitro ubiquitination assays
ER-NIH3T3 post-nuclear supernatant preparations were prepared from cultures of 50 × 10 6 cells grown in 100 mm dishes, which were trypsinized, pelleted by centrifugation for 5 min at 1300×g, washed twice with 6 ml cold PBS, and resuspended to a total volume of 3 ml in 50 mM Tris-HCl, pH 7.6, 50 mM NaCl, and 2 mM DTT. The cells were frozen at − 80°C, thawed, and passed 15 times through a 0.22 gauge needle to complete the lysis. This material was centrifuged for 5 min at 2000×g and the resulting post nuclear supernatant removed. The protein concentration was determined using the Bradford reagent. In vitro ubiquitination assays with the ER-NIH3T3 or HeLa cytoplasmic preparations and purified HAV 3C protease were performed essentially as previously described (Lawson et al., 1999) . Briefly, 3 to 5 mg/ml of cytoplasmic protein preparations were incubated for 10 min at room temperature with a buffered solution containing an ATPregenerating system and 1.5 μM ubiquitin aldehyde. Five μM HAV 3C protease protein and 100 μM methylated ubiquitin were then added and the mixtures incubated at 37°C. Aliquots were removed from the mixtures at 0 and 2 h and analyzed by SDS-PAGE and Western blotting as described above.
Evaluation of expressed 3C protease catalytic activity
For experiments designed to detect in vivo expressed 3C protease catalytic activity, the pEGSH-E3C-or pEGSH-H3C-transfected cells were each cultured in 100 mm dishes to 70 to 80% confluency in standard medium containing 200 μg/ml G418 and 100 μg/ml hygromycin B. This medium was then replaced with either inducing medium containing 10 μM ponasterone A and 50 μM MG132 or non-inducing medium containing 50 μM MG132 and incubated for 16 h at 37°C in 5% CO 2 . The cells were washed with PBS and harvested by scraping with a rubber policeman into 1 ml PBS/plate. The cells were pelleted by centrifugation for 2 min at 1300×g, resuspended in 1 volume of cold 10 mM HEPES, pH 7.5, 10 mM KCl, 1.5 mM MgCl 2, and 2 mM DTT. The suspension was subjected to three freeze-thaw cycles, and the insoluble material was removed by centrifugation for 2 min at 1300×g. The protein concentrations of the final whole cell lysates were determined using the Bradford reagent.
35 S-labeled viral polyprotein substrates were prepared by in vitro transcription and translation based upon the previously described procedures (Oberst et al., 1993) . pE5LVP0 (Parks et al., 1986) was linearized by digestion with XbaI and pEXT7-HM/HAS-VP2-2A/(E/S) (Probst et al., 1998) was linearized by digestion with XhoI. Both plasmids were transcribed using T7 RNA polymerase. The RNA was purified and translated in reaction mixtures containing rabbit reticulocyte lysate and L-[ 35 S]-methionine. 3C protease activity assay reaction mixtures contained 2.5 mg/ml whole cell lysate protein in 20 mM HEPES, pH 7.5, 2 mM EDTA, 1 mM DTT, and 40% by volume of the appropriate polyprotein in vitro translation reaction mixture. Positive control reactions contained 5 μM purified EMCV or HAV 3C protease in place of the cell lysate protein.
The reaction mixtures were incubated at 30°C for the indicated times, and aliquots were removed for analysis by SDS-PAGE and phosphorimaging.
Evaluation of 3C protease expression effects on cell viability
The effects of EMCV and HAV 3C protease gene expression on cell viability were evaluated by incubating the pEGSH-E3C-and pEGSH-H3C-transfected cells under non-inducing and inducing conditions in the absence or presence of proteasome inhibitor, with the ER-NIH3T3 and pEGSH-Luc-transfected cells as controls. 56,000 cells/well were seeded into 12-well plates and incubated for 24 h at 37°C in 5% CO 2 in standard medium containing 200 μg/ml G418 and 100 μg/ml hygromycin B. This medium was then replaced with one of four media: non-inducing medium, non-inducing medium containing 10 μM lactacystin, inducing medium containing 10 μM ponasterone A, or inducing medium containing both 10 μM ponasterone A and 10 μM lactacystin. The cells were then incubated at 37°C in 5% CO 2 , and beginning 8 h later the cells were observed and imaged at 4-h intervals using a Moticam 1000 CCD camera mounted on an Olympus model CK40-F100 phase contrast microscope. After 20 h the cells were washed with PBS, trypsinized, and suspended in PBS containing 0.2% (w/v) trypan blue. Living cells were quantified using a hemacytometer. These observations and the cell counting protocol were carried out in triplicate for each growth condition.
Cell fractionation and 3C protease localization
To prepare cytoplasmic and nuclear soluble protein fractions from 3C protease expressing cells, cells were cultured in either in 6-well plates or 100 mm dishes to 70 to 80% confluency and induced with ponasterone A in the presence of 25 μM MG132 as described above. For each fractionation, cells from four to six wells, for 6-well plates, or 6 to 12 100 mm dishes were trypsinized, pelleted by centrifugation for 2 min at 1300×g, and washed twice with 10 volumes of cold PBS. The cytoplasmic and nuclear lysate soluble protein fractions were obtained using the NE-PER nuclear and cytoplasmic extraction reagents following the manufacturer's protocol and were immediately frozen in aliquots at − 80°C. The protein concentrations of the fractions were determined using the Bradford reagent.
The cytoplasmic and nuclear fractions were tested for the presence of the expressed 3C protease by subjecting 20 μg of protein from each fraction to SDS-PAGE and Western blotting as described above. G3PDH and PARP were used as cytoplasmic or nuclear markers, respectively, and were detected in the blots using anti-G3PDH or anti-PARP monoclonal antibodies and anti-mouse IgG alkaline phosphatase conjugated secondary antibodies via the same procedures described above.
To examine nuclear extract fractions for the presence of polyubiquitin-EMCV 3C protease conjugates, 100 μg aliquots of nuclear fraction protein were mock immunoprecipitated, without antibody, or immunoprecipitated with anti-3C protease antibody. The precipitates were subjected to SDS-PAGE and Western blotting using anti-3C protease or anti-ubiquitin primary antibodies and alkaline phosphatase-conjugated secondary antibodies. The blots were developed using the ECF alkaline phosphatase reagent as described above.
